SYRS - Syros Pharmaceuticals, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

SYRS

SYROS PHARMACEUTICALS, INC.

OTC

$0.00

▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$2.68 K

52w High$0.02

52w Low$0.00

Dividend Yield—

Frequency—

P/E—

Volume904

Shares Out.26.83M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

James E. Bradner

COMPENSATION 2026

Salary$479,092

Stock Awards$369,460

Incentive Plan Pay$192,455

All Other Comp.$690

Total$1,041,697

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 30, 2016

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$30.00

Target Low$5.00

Target Median$15.00

Target Consensus$16.67

UPCOMING EARNINGS

DateAug 31, 2026

DayMonday

Rev. Est.—

AUG

MON

SPLIT RECORD

DATE	TYPE	RATIO
2022-09-19	Reverse	1:10

PRICE

$0.00 ▲ UP 0.00% (+$0.00)

OVERLAYS

About Syros Pharmaceuticals, Inc.

https://www.syros.com ↗

Syros Pharmaceuticals develops gene control medicines for cancer and monogenic diseases, with lead candidates in clinical trials including Tamibarotene, SY-2101, and SY-5609.

INDUSTRY

Biotechnology

A PRODUCT SYROS PHARMACEUTICALS, INC. IS KNOWN FOR

Tamibarotene

Tamibarotene, an oral RARα agonist developed by Syros Pharmaceuticals for HR-MDS and AML, faced setbacks after its Phase 3 trial failed to meet primary endpoints and a Phase 2 AML trial was discontinued in late 2024.